Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal prophylactic enoxaparin dose in critically ill septic patients
2005-002381-10Phase 4Completed
- Sponsor
- Dept anaesthesiology and intensive care
- Start
- Jun 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enoxaparin in sepsis, sponsored by Dept anaesthesiology and intensive care. Primary endpoint: Coagulation parameters over 24 hours. Started Jun 2005; status: completed.
02
Drugs
enoxaparin
03
Conditions
sepsis
Beyond the preview
Go deeper on 2005-002381-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002381-10.